Is there a place for cannabidiol (CBD) in the treatment of psychiatric disorders?

    Cannabidiol (CBD) is considered to be a nonpsychotomimetic and nonpsychoactive derivative of Cannabis sativa. It was patented by the US Department of Health and Human Services in 2003 as an antioxidant and neuroprotectant. CBD has a complex mode of action which includes inverse agonism (functionally an antagonist) of CB1 and CB2 cannabinoid receptors, mild monoamine […]